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In this study, we tested the hypothesis that the glycosylation of the pathogenic isoform of the prion protein
(PrPSc) might encode the selective neurotropism of prion strains. We prepared unglycosylated cellular prion
protein (PrPC) substrate molecules from normal mouse brain by treatment with PNGase F and used reconstituted serial protein cyclic misfolding amplification reactions to produce RML and 301C mouse prions
containing unglycosylated PrPSc molecules. Both RML- and 301C-derived prions containing unglycosylated
PrPSc molecules were infectious to wild-type mice, and neuropathological analysis showed that mice inoculated
with these samples maintained strain-specific patterns of PrPSc deposition and neuronal vacuolation. These
results show that PrPSc glycosylation is not necessary for strain-dependent prion neurotropism.
different prion strains produce distinctive ratios of PrPSc glycoforms upon serial passage (9). Studies of transgenic mice
show that PrPC glycosylation influences patterns of prion neurotropism in a strain-dependent manner (11, 35). Studies with
human brain specimens have shown that the regional distribution of PrPSc glycoforms is heterogenous in the sporadic but
not the variant form of Creutzfeldt-Jakob disease (21). Taken
together, these observations suggest the possibility that various
patterns of PrPSc glycosylation may direct the regional neurotropism of prion strains. However, technical difficulties in manipulating PrPSc glycosylation have thus far precluded direct
experimental testing of this hypothesis.
A series of recent advances has provided a new opportunity
to produce infectious unglycosylated PrPSc molecules in vitro
by using serial protein misfolding cyclic amplification
(sPMCA) reactions (7, 26), a cell-free prion amplification technique that faithfully preserves the strain properties of the initial seed material (6). Here, we use reconstituted sPMCA
reactions to produce unglycosylated PrPSc molecules derived
from two mouse prion strains associated with easily distinguishable patterns of neurotropism (6). Neuropathological
analysis of animals infected with these inocula shows that PrPSc
glycosylation is not required for the maintenance of strainspecific neurotropisms.

Prion diseases are fatal neurodegenerative illnesses that occur in genetic, sporadic, and infectious forms (18). A critical
pathogenic event common to the sporadic and infectious forms
of prion disease is the misfolding of a host-encoded prion
protein (PrPC) into a pathogenic isoform (PrPSc). Infectious
wild-type prions have been produced de novo from purified
PrPC, lipid, and synthetic poly(A) RNA molecules (13), confirming the proposition that the infectious agent lacks replicating nucleic acids (28). However, it remains unknown whether
native mammalian prions contain only PrPSc molecules, as
proposed by the “protein-only” hypothesis or, alternatively,
whether the maintenance of an infectious conformation might
require a physical interaction between PrPSc molecules and
structural cofactors such as polyanions (12, 17).
Interestingly, prions can exist as distinct “strains” characterized by unique clinical features and patterns of neurotropism
that are faithfully recapitulated upon serial passage within the
same animal species (3, 4). Studies with yeast models and
recombinant proteins indicate that prion proteins can adopt
multiple, self-propagating conformations (19, 20, 24, 33, 34).
However, it is difficult to explain the selective and self-propagating neurotropism of native mammalian prion strains on the
basis of differential PrP polypeptide folding alone, and it remains unknown how neurons from different brain regions discriminate between different prion strains (11).
Mature PrP molecules have two N-linked glycosylation sites
at residues 180 and 196 and therefore can be di-, mono-, or
unglycosylated (14, 22). Interestingly, different ratios of PrPC
glycoforms are found in different brain regions (2, 10, 32), and

MATERIALS AND METHODS
Reagents. Mouse prion stain RML was kindly provided by Stanley Prusiner
(University of California, San Francisco). Mouse prion strain 301C was generated by serially passaging an isolate of bovine spongiform encephalopathy prions
through C57BL mice. Mice used in inoculation experiments were female,
C57BL6, aged 35 days, and purchased from Charles River (Wilmington, MA).
Prnp0/0 mice were kindly provided by David Harris (Washington University, St.
Louis, MO) with permission from Charles Weissmann (Scripps Florida, Jupiter,
FL). Immunoglobulin G monoclonal antibody (MAb) 27/33 was raised against
purified recombinant mouse PrP 90-231 (kindly provided by Ilia Baskakov, University of Maryland Biotechnology Institute, Baltimore, MD) and subsequently
purified from hybridoma cells by Bio Express (West Lebanon, NH). Noninfectious mouse brains were purchased from BioChemed (Winchester, VA). These
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brains were from CD1 mice, both sexes, aged 15 weeks, and were immediately
snap-frozen in liquid nitrogen after removal.
Preparation of brain homogenates. In several instances, brain homogenates
were used either directly as inocula or as reagents for PMCA reactions; they were
prepared as follows. One mouse brain (normal, Prnp0/0, RML infected, or 301C
infected) weighing ⬃0.5 g was homogenized using either a Potter homogenizer
(for normal brains) or a disposable plastic homogenizer (VWR Scientific, Boston, MA) (for infected brains) in 5 ml of cold phosphate-buffered saline (PBS)
(without calcium or magnesium). The resulting 10% (wt/vol) homogenate was
then centrifuged at 200 ⫻ g for 30 s, and the supernatant was collected and frozen
at ⫺80°C.
Purification of native and unglycosylated PrPC. Unglycosylated PrPC was
purified as previously described (26). Briefly, 12 mouse brains were Potter homogenized in 40 ml of cold buffer A (20 mM MOPS [morpholinepropanesulfonic
acid] [pH 7.0] and 150 mM NaCl) with Complete EDTA-free protease inhibitor
(Roche, Indianapolis, IN). The homogenate was centrifuged at 200 ⫻ g for 30 s,
and the supernatant was removed and centrifuged again at 3,200 ⫻ g for 20 min.
The resulting pellet was resuspended using a Dounce homogenizer in 30 ml of
cold buffer A with Complete EDTA-free protease inhibitor. Four milliliters of
10% deoxycholate–Triton X-100 detergent was added, and the mixture was
incubated on ice for 30 min. After solubilization, the homogenate was centrifuged at 100,000 ⫻ g for 30 min. The supernatant was then added to a preequilibrated 2-ml immobilized metal ion affinity chromatography-CuSO4 column (GE
Healthcare, Piscataway, NJ). The column was washed with 10 ml of wash buffer
(10 mM imidazole in buffer A [pH 7.0] and 0.5% Triton X-100), and eluted with
10 ml elution buffer (20 mM MES [morpholineethanesulfonic acid] [pH 6.4], 150
mM imidazole in buffer A [pH 7.0], 150 mM NaCl, and 1% Triton X-100). Next,
the eluate was applied to a preequilibrated 2-ml SP Sepharose cation exchange
column (Sigma, St. Louis, MO). The SP column was washed with 10 ml of SP
wash buffer (20 mM MOPS [pH 7.0], 250 mM NaCl, and 0.5% Triton X-100) and
eluted in 8 ml of SP elution buffer (20 mM MOPS [pH 7.5], 500 mM NaCl, and
0.5% Triton X-100). The resulting eluate was designated the “native” preparation. To remove the N-linked glycans from PrPC, 50 l (⬃25,000 units) glycerolfree peptide N-glycosidase F (PNGase F) (New England Biolabs, Beverly, MA)
was added to 500 l of the SP eluate. This mixture was then incubated for 24 h
at 37°C. After this initial incubation, another 50 l of PNGase F was added to the
tube and incubated for another 24 h at 37°C. To repurify deglycosylated PrPC,
the sample was mixed with 200 l immobilized metal ion affinity chromatography-CuSO4 resin and incubated with end-over-end rotation for 30 min at 4°C.
The protein-resin slurry was poured into a column support and washed with 20
ml of wash buffer followed by elution with 500 l of elution buffer. The eluate
was put into a 3,500-molecular-weight-cutoff Slide-A-Lyser (Pierce, Rockford,
IL) and dialyzed overnight into buffer C (20 mM MOPS [pH 7.5], 150 mM NaCl,
and 0.5% Triton X-100). The final sample was termed unglycosylated PrPC
substrate.
sPMCA. Serial prion propagation using sPMCA was performed using a
method described previously by Castilla et al. (7). To avoid cross-contamination,
only one strain was used within the sonicator at a time. Also, as a precautionary
measure to minimize the possibility of residual contamination between different
runs (which can be caused by tube leakage during PMCA), the microplate cup
horn was decontaminated between strains by soaking in 100% household bleach
(60,000 ppm sodium hypochlorite) for 5 min with one 30-s pulse and then rinsed
with deionized, filtered H2O. Furthermore, all strain work was carried out in
laminar-flow biosafety cabinets with disposable surfaces and aerosol barrier tips.
To produce substrate mixtures for normal brain homogenate or Prnp0/0 “ablated” brain homogenate sPMCA (Abl-sPMCA) reactions, 75 l of 10% normal
mouse brain homogenate or 10% ablated brain homogenate (homogenate from
Prnp0/0 mice) was mixed with 15 l of TEI (3.33% Triton X-100, 33.33 mM
EDTA, 333.33 mM imidazole [pH 8.0]). On the first day, 10 l of 10% brain
homogenate from RML- or 301C-infected animals was diluted 1:100 in PBS and
added to a 0.5-ml thin-walled PCR tube. Reaction tubes were subjected to
PMCA for 24 h using a Misonix s3000 programmable sonicator equipped with a
microplate horn (Misonix, Farmingdale, NY) containing 350 ml of water. The
sonicator was set to deliver 30-s bursts every 30 min at output 6.5. Temperature
within the microplate horn was maintained by flowing heated water through
aluminum coils surrounding the horn. Sample tubes were mounted in a holder
that prevents lid opening and holds tubes ⬃3 mm from the horn surface. After
24 h, the tubes were removed from the sonicator, and 10 l of the reaction
mixture volume was added to a new tube containing fresh substrate. This was
carried out for 15 consecutive cycles, effectively diluting the original inoculum
1015-fold. To produce substrate mixtures for native and unglycosylated PrPC
sPMCA reactions, 37.5 l of either native or unglycosylated PrPC preparations
(prepared as described above) was mixed with 25 l of 10% ablated brain
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homogenate, 15 l of TEI, and 12.5 l of buffer B (20 mM MOPS [pH 7.5], 150
mM NaCl, 1% Triton X-100). On the first day, 10 l of 10% brain homogenate
from RML- or 301C-infected animals diluted 1:100 in PBS was added to the
reaction tube. Tubes were subjected to the same sonicator settings described
above. After 24 h, 10 l of the reaction mixture was added to a new tube
containing fresh substrate. This was carried out for a total of 15 days.
Preparation of inocula. For each sPMCA-generated inoculum, five tubes containing 200 l reaction mixture/tube were prepared. Each tube was spiked with
20 l of material from the day 15 tube of that group (prepared as described
above). These tubes were subjected to 48 h of sonication at the settings described
above. The five samples in each group were pooled together and centrifuged at
200 ⫻ g for 30 s. The supernatant was transferred to a new tube and centrifuged
again at 200 ⫻ g for 30 s. The supernatant was transferred to a new tube and
passed through a 25-gauge needle five times, followed by passage through a
28-gauge needle five times. The material was then centrifuged at 100,000 ⫻ g for
1 h at 4°C. The supernatant was removed, and the pellet was resuspended in 500
l PBS containing 1% Triton X-100. This material was then sequentially passed
through increasing-gauge needles (18, 23, 25, and 28 gauge) five times each. An
aliquot of the resuspended material was analyzed for PrPSc content by Western
blotting. Another aliquot was diluted 1:10 into PBS plus 5 mg/ml bovine serum
albumin to prepare the inoculum samples. For brain-derived inocula, 100 l of
10% (wt/vol) prion-infected brain homogenate was diluted 1:10 into PBS plus 5
mg/ml bovine serum albumin.
Scrapie inoculation and diagnosis. To avoid contamination, inoculations of
groups from different strains were performed on separate days in laminar-flow
biosafety cabinets using disposable syringes, gloves, and surfaces. Intracerebral
inoculations were performed using 28-gauge hypodermic needles inserted into
the parietal lobe. Each animal received 30 l of inocula. After inoculation, mice
were examined daily by veterinary staff blinded to the experimental groups.
Standard diagnostic criteria were used to identify animals showing signs of
scrapie (5, 29).
Neuropathology. Animals whose deaths were imminent were euthanized by
CO2 inhalation, and their brains were removed quickly using sterile-packaged
dissection instruments on disposable surfaces to avoid cross-contamination.
Brains were fixed by immersion in 10% buffered formalin for up to 1 week.
Brains were then sectioned in the sagittal and parasagittal planes at ⬃2- to 3-mm
intervals and placed into tissue-processing cassettes. The cassettes were immersed into 90% formic acid for 60 to 90 min and then placed in 10% formalin.
Tissue was then embedded in paraffin and cut into 4-m sections. These sections
were then stained with hematoxylin and eosin or anti-PrP antibody (immunohistochemistry [IHC]). A single neuropathologist, who was blinded to the experimental groups, examined all of the slides. Each brain was scored for the degree
of vacuolation in six different brain regions: parietal cortical layers 1 and 2, layers
3 and 4, and layers 5 and 6; hippocampus; cerebellum; and brain stem. Scoring
was performed using ordinal variables as previously described (7, 16): 0, no
lesions; 0.5, minimum vacuolation (two to three vacuoles in half a 40⫻ objective
field); 1.0, little vacuolation (three to five vacuoles in half a field); 2.0, moderate
vacuolation (several vacuoles evenly scattered); 3.0, extensive vacuolation (many
vacuoles distributed in half a field); 4.0, severe vacuolation (numerous vacuoles
often coalescing). Slides from adjacent sections were also prepared for antigen
retrieval using CitraPlus reagent (Biogenex, San Ramon, CA) (pH 6.23) and
pressure steaming to 126°C (16 lb/in2), followed by immunostaining with MAb
27/33 (final working concentrations, 3 g/ml) by using a Biogenix i6000 automated stainer. Immunodeposition was visualized by using a horseradish peroxidase–3,3⬘-diaminobenzidine MultiLink detection kit (Biogenex) according to the
manufacturer’s recommended protocol. Each brain was scored for anti-PrP immunodeposition as follows: 0, no deposition; 1.0, minimal deposition; 2.0, moderate deposition; 3.0, extensive deposition.
PrPSc detection. All protease-digested samples (with proteinase K) were incubated with 25 g/ml proteinase K for 30 min at 37°C with shaking at 800 rpm
in an Eppendorf Thermomixer (Fisher Scientific, Pittsburgh, PA). An equal
volume of 2⫻ sodium dodecyl sulfate (SDS) sample buffer was added, and
samples were boiled for 10 min at 95°C. SDS-polyacrylamide gel electrophoresis
(PAGE) was then performed using 1.5-mm 12% polyacrylamide gels with an
acrylamide/bisacrylamide ratio of 29:1. The gel was then transferred to a methanol-charged polyvinylidene difluoride membrane (Millipore, Billerica, MA) using a Transblot SD semidry transfer cell (Bio-Rad, Hercules, CA). The transfer
was set at 2 mA/cm2 for 30 min. To visualize PrP signals, the membrane was
incubated in Hood skim milk (Chelsea, MA) buffered with TBST (10 mM Tris
[pH 7.1], 150 mM NaCl, 0.1% Tween 20). The blocked membrane was then
incubated overnight at 4°C with 27/33 and diluted 1:25,000 (0.12-g/ml final
concentration). The membrane was then washed three times for 10 min in TBST.
Last, the membrane was incubated for 1 h with horseradish peroxidase-labeled
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FIG. 1. Western blot showing samples of inocula. Lanes 1 and 2
show nondigested PrPC used as a substrates in sPMCA reactions.
Strong reactivity against the ⬃18-kDa C1 proteolytic fragment (37) is
characteristic of primary MAb 27/33 used to develop this Western blot.
The remaining samples were subjected to limited proteolysis with
proteinase K (⫹PK). Some proteolyzed samples were also deglycosylated by treatment with PNGase F (⬃5,000 units) prior to SDSPAGE, as indicated. The bracket indicates a strain-specific difference
in electrophoretic mobility between unglycosylated PrPSc bands derived from strains 301C and RML.

anti-mouse immunoglobulin G secondary antibody conjugate (GE Healthcare)
diluted 1:5,000 in TBST. Again, the membrane was washed four times for 10 min
each in TBST. Blots were developed with West Femto (Pierce, Rockford, IL)
chemiluminescence substrate, and images were captured digitally using a Fuji
(Fujifilm, Tokyo, Japan) LAS-3000 chemiluminescence documentation system.
Relative molecular masses were determined by comparison to prestained standards from Fermentas (Hanover, MD). Digitally captured images of Western
blots were subjected to densitometric analysis using the program Image Gauge v.
4.22 (Fuji). For each signal, replicate measurements were obtained (n ⫽ 3), and
values were averaged.
Enzymatic deglycosylation. To deglycosylate PrPSc molecules, 100 l of each
sample was protease digested as described above. To inactivate proteinase K,
phenylmethylsulfonyl fluoride dissolved in ethanol was added to each sample for
a final concentration of 1 mM. Samples were then diluted to 750 l in PBS and
10% Sarkosyl (Sigma) and centrifuged at 100,000 ⫻ g for 1 h at 4°C. Supernatants were removed, and pellets were resuspended into 100 l of 1⫻ glycoprotein
denaturing buffer (New England Biolabs) and boiled for 10 min at 95°C. Next, 11
l of 10⫻ G7 reaction buffer and 11 l of 10% NP-40 (both from New England
Biolabs) were added to the reaction tubes and mixed. Ten microliters of PNGase
F enzyme (⬃5,000 units) was then added to the tubes and incubated overnight at
37°C. To stop the reaction, an equal volume of 2⫻ SDS sample buffer was added
to each tube and boiled for 10 min at 95°C.
Urea denaturation assay. Samples containing 8% (wt/vol) brain homogenate
in PBS without calcium or magnesium plus 2% Triton were indirectly sonicated
using a Misonix 3000-MPD programmable sonicator equipped with a microplate
horn at power 7.5 for 30 s. Following sonication, 10-l samples were diluted 1:4
with various aqueous solutions to achieve final urea concentrations of 0, 1, 2, 3,
4, 5, and 6 M. Adjusted samples were incubated at 50°C for 3 h with shaking at
800 rpm in a Thermomixer apparatus (Eppendorf, Westbury, NY). After incubation, 80 l of PBS–1% Triton X-100 containing 60 g/ml proteinase K was
added to each tube, and samples were incubated for 1 h at 37°C with shaking in
a Thermomixer apparatus. After digestion, 40 l of 4⫻ SDS sample buffer was
added to each tube, and the sample was boiled for 10 min. Quantified Western
blot signals were best fitted using a sigmoidal dose-response equation with a
variable slope using the program Prism 5.0a (GraphPad Software, La Jolla, CA).

RESULTS
To produce unglycosylated sPMCA (UN-sPMCA) inocula,
we performed 16 rounds of reconstituted sPMCA reactions
using enzymatically deglycosylated mouse PrPC as a substrate
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and mouse prion strains RML and 301C as seeds in the first
round. Western blot analysis confirmed the presence of protease-resistant PrPSc molecules in the final (round 16) UNsPMCA samples for both strains (Fig. 1, lanes 7 and 8). Interestingly, the UN-sPMCA(301C) product exhibited slightly
slower mobility by SDS-PAGE following proteinase K digestion than the UN-sPMCA(RML) product, corresponding to
the similar ⬃2-kDa difference observed between these two
strains in the migrations of their proteinase K-digested,
PNGase F-treated brain-derived PrPSc molecules (Fig. 1, compare lanes 7 and 8 with lanes 5 and 6) (6). This observation
indicates that the strain-specific, conformation-dependent biochemical property of electrophoretic mobility following proteinase K digestion appears to be preserved during sPMCA
propagation using unglycosylated PrPC substrate. Control samples in which the initial input seed for each prion strain was
serially diluted and mock propagated in the absence of PrPC
substrate (Abl-sPMCA) yielded no detectable PrPSc molecules
by Western blotting (Fig. 1, lanes 9 and 10).
We injected normal C57BL mice intracerebrally with brainderived RML, 301C, or the final-day products of 16 round
sPMCA reactions originally seeded with these prion strains.
Whereas mice inoculated with brain-derived prions or the day
16 products of sPMCA reactions using unglycosylated PrPC
substrate developed clinical prion disease with incubation
times ranging from ⬃170 to ⬃350 days, mice inoculated with
the day 16 products of negative control sPMCA reactions lacking PrPC substrate (Abl-sPMCA) remained healthy ⬎400 days
after inoculation (Table 1). It is worth noting that the concentration of PrPSc is ⬃40-fold greater in the brain-derived inocula than in the UN-sPMCA inocula, and therefore, it is difficult
to interpret the differences in prion incubation times between
those groups.
Western blot analysis confirmed the presence of proteaseresistant PrPSc molecules in the brains of mice from each
group with clinically diagnosed prion disease (Fig. 2). Di-,
mono-, and unglycosylated PrPSc molecules were all present in
the brains of mice infected with UN-sPMCA(301C) and UNsPMCA(RML) inocula that contained only unglycosylated
PrPSc molecules (Fig. 2, lanes 9 and 10); these results are
similar to and consistent with those previously reported by Tuzi
et al., in which an inoculum containing unglycosylated PrPSc
molecules originally derived from mouse prion strain 79A was
infectious to wild-type mice and all three PrPSc glycoforms
were present in the brains of recipient mice (35).

TABLE 1. Prion incubation times in wild-type mice inoculated
intracerebrally with brain-derived and sPMCA-generated prions
Inoculum

No. of infected
mice/total no.
of mice

Mean incubation time
(days) ⫾ SEM

Brain RML
Brain 301C
UN-sPMCA(RML)
UN-sPMCA(301C)
Abl-sPMCA(RML)
Abl-sPMCA(301C)
Homog-sPMCA(301C)
Native sPMCA(301C)

5/5
9/9
13/13
6/7
0/8
0/8
8/8
8/8

169 ⫾ 2
193 ⫾ 1
202 ⫾ 2
348 ⫾ 26a
⬎407
⬎407
265 ⫾ 63
237 ⫾ 32

a

Ongoing experiment.
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FIG. 2. Western blot showing representative brain homogenates
from inoculated animals. Where indicated, samples were subjected to
limited proteolysis or deglycosylated by treatment with PNGase F
(⬃5,000 units). The bracket indicates a strain-specific difference in
electrophoretic mobility between unglycosylated PrPSc bands derived
from strains 301C and RML. The segment of the blot containing lanes
1 to 6 was exposed for 1 min, and the segment containing lanes 7 to 16
was exposed for 8 min. ⫹PK, with proteinase K treatment.

The brains of mice inoculated with either brain-derived
RML or UN-sPMCA(RML) prions contained a comparatively
even distribution of the three PrPSc glycoforms (Fig. 2, lanes 3
and 9), whereas diglycosylated PrPSc appeared to be relatively
enriched in the brains of mice inoculated with either brainderived 301C or UN-sPMCA(301C) prions (Fig. 2, lanes 4 and
10). Densitometric quantification of the ratios of deglycosylated:unglycosylated PrPSc molecules on unsaturated Western
blot images yielded values of 0.7 and 0.6 for the brain-derived
RML and UN-sPMCA(RML) samples, respectively, and 1.6
and 1.8 for the brain-derived 301C and UN-SPMCA(301C)
samples, respectively. Furthermore, enzymatic deglycosylation
revealed that the proteinase K-resistant PrPSc bands in samples from mice inoculated with either brain-derived 301C or
UN-sPMCA(301C) prions migrated ⬃2 kDa more rapidly than
the corresponding bands in samples from mice inoculated with
either brain-derived RML or UN-sPMCA(RML) prions (Fig.
2, lanes 5, 6, 11, and 12). Another feature preserved in the
brains of animals inoculated with brain-derived 301C and UN-
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sPMCA(301C) prions is the lack of the ⬃19-kDa calpaingenerated C2 fragment (40), which can be appreciated for
samples from animals inoculated with brain-derived RML and
UN-sPMCA(RML) prions that were treated with proteinase K
(Fig. 2, compare lanes 2 and 8 to lanes 1 and 7). A urea
denaturation assay revealed that PrPSc molecules in animals
inoculated with either brain-derived RML or UN-sPMCA(RML)
prions (half-maximal denaturation concentration for both
groups of ⬃3.5 M urea) were significantly more stable than
PrPSc molecules in animals inoculated with either brain-derived 301C or UN-sPMCA(301C) prions (half-maximal denaturation concentration for both groups of ⬃2.5 M urea) (see
Fig. S1 in the supplemental material). Taken together, these
results indicate that several biochemical properties of the prion
strains analyzed (i.e., PrPSc glycosylation profile, electrophoretic mobility following proteinase K digestion, and the
presence of a detectable C2 proteolytic fragment) were preserved in vivo by the sPMCA-generated unglycosylated PrPSc
molecules. As expected, no PrPSc molecules were detected in
the brains of age-matched, clinically well-appearing mice
that had been inoculated with Abl-sPMCA(301C) and AblsPMCA(RML) products (Fig. 2, lanes 15 and 16), consistent
with the lack of prion infectivity in those control samples.
Additional control experiments showed that PrPSc molecules
in the brains of mice inoculated with sPMCA products of
reactions using crude brain homogenate (Homog-sPMCA) or
reconstituted native PrPC substrates (native sPMCA) also retained their strain-specific patterns of electrophoretic mobility
(see Fig. S2 in the supplemental material).
Microscopic analysis of the neuropathology of prion-infected mice in each of the experimental groups (i.e., inoculated
with brain-derived or UN-sPMCA prions) revealed spongiform degeneration, PrP immunodeposition, and reactive astrogliosis, whereas the brains of mice infected with Abl-sPMCA
control inocula lacked all of these characteristics (Fig. 3).
Within the cerebral cortex of RML-infected animals, both vacuolation and PrP immunodeposition could be better appreci-

FIG. 3. Representative histological fields of cerebral cortex and cerebellum. Shown is PrP immunohistochemical staining from animals injected
with brain-derived or sPMCA-generated 301C and RML prions. (Top) Animals injected with brain-derived prions. (Middle) Animals injected with
UN-sPMCA prions. (Bottom) Control animals injected with Abl-sPMCA. (A) Cerebral cortex. Arrows indicate the location of strain-specific
staining within layers 3 and 4 of the cerebral cortex. Scale bar, 200 m. (B) Cerebellum. Arrows indicate the location of PrP aggregates. Scale bar,
100 m.

VOL. 83, 2009

ated at a higher magnification (see Fig. S3 in the supplemental
material). Strikingly, PrP immunodeposition in the cerebral
cortex of mice inoculated with either brain-derived 301C or
UN-sPMCA(301C) prions appeared to be highly concentrated
in layers 3 and 4, whereas PrP immunodeposition appeared to
be evenly distributed throughout all six cortical layers in
mice inoculated with either brain-derived RML or UNsPMCA(RML) prions (Fig. 3A). Furthermore, there appeared
to be many discrete ⬃1- to 30-m PrP aggregates in the cerebellum of mice inoculated with either brain-derived 301C or
UN-sPMCA(301C) prions, whereas no aggregates larger than
2 m could be seen in the cerebellum of mice inoculated with
either brain-derived RML or UN-sPMCA(RML) prions, and
PrP immunodeposition appeared to be diffusely distributed
throughout the cerebellar cortex in those animals (Fig. 3B).
Taken together, these results indicate that characteristic patterns of PrP immunodeposition in the cerebral cortex and
cerebellum, which are easily distinguishable between strains
RML and 301C, are preserved by PrPSc molecules lacking
glycosylation. In additional control experiments, we also observed the concentration of PrP immunodeposition in cortical
layers 3 and 4 and the presence of discrete cerebellar PrP
aggregates in the brains of mice inoculated with sPMCA-propagated 301C prions using either normal mouse brain homogenate or partially purified PrPC reconstituted with Prnp0/0
brain homogenate (native) as a substrate, confirming that neither the sPMCA technique itself nor the reconstitution of
partially purified PrPC molecules with Prnp0/0 brain homogenate influences the ability of PrPSc molecules to propagate and
encode these distinctive neurotropic features (see Fig. S4 in
the supplemental material).
To compare the patterns of neurotropism in the various
groups of prion-infected mice at a broader level, we compiled
and analyzed regional profiles of PrP immunodeposition and
neuronal vacuolation scores. The results showed that for both
strains 301C (Fig. 4A and C) and RML (Fig. 4B and D), the
regional profiles of PrP immunodeposition and vacuolation
were similar for brain-derived and UN-sPMCA prions. The
regional variations between the two strains were more easily
distinguished by PrP immunodeposition (Fig. 4, compare A
and B) than vacuolation (Fig. 4, compare C and D), primarily
because the increased PrP deposition in layers 3 and 4 appeared not to be associated with increased levels of vacuolation
in those layers. Taken together, these results indicate that the
unglycosylated PrPSc molecules can encode strain-specific regional patterns of PrPSc accumulation. Data were analyzed
using Stat 9.0 (Stata statistical software release 9.0; Stata Corporation, College Station, TX). For each of the experimental
groups, we compared vacuolation and immunohistochemistry
characteristics in all six brain regions using the Wilcoxon rank
sum test. This statistical approach identified no significant differences in vacuolation between the brain-derived 301C and
UN-sPMCA(301C) groups or in IHC staining between the
brain-derived RML and the UN-sPMCA(RML) groups.
Global differences in the absolute magnitudes of IHC staining
between the brain-derived 301C and UN-sPMCA(301C)
groups and of vacuolation between the brain-derived RML
and the UN-sPMCA(RML) groups rendered these comparisons nonamenable to statistical analysis, but Fig. 4 shows that
the patterns of these characteristics across brain regions also
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appear very similar in regional profile. As an additional control, we also examined the patterns of PrP deposition in animals infected with Homog-sPMCA(RML) and HomogsPMCA(301C) inocula. As expected, the regional profiles of
these groups were similar to those of the UN-sPMCA(RML)
and UN-sPMCA(301C) groups, respectively (compare Fig. S5
in the supplemental material to Fig. 4A and B).
DISCUSSION
In this study, we report for the first time that PrPSc glycosylation is not required for the maintenance of strain-dependent
prion neurotropism. A corollary of this result is that the selective neurotropism of mammalian prions must be encoded either by strain-specific differences in PrPSc polypeptide conformation or by putative accessory molecules such as lipids or
polyanions (13, 17, 38, 39).
The phenomenon of strain-specific neurotropism implies
that neurons must be able to recognize and distinguish between different prion strains. The hypothesis, which our findings refute, that glycosylation might be the distinguishing feature of PrPSc molecules recognized by cells was originally
attractive for several reasons. First, the glycans are large surface-exposed structures that appear to be well positioned to
mediate cell target interactions (41). Second, there is great
diversity in PrP glycosylation, which could therefore provide a
basis for diverse patterns of neuronal targeting (30). Third,
some prion strains appear to be associated with distinctive
PrPSc glycoform patterns (9). Fourth, PrPC glycoform patterns
vary in different brain regions (2, 10, 32) and in different
neuronal populations (15), and it is conceivable that prions
containing a specific ensemble of PrPSc glycoforms might prefer to propagate in neurons with a similar ensemble of PrPC
glycoforms. Finally, PrPC glycosylation influences both strain
and cross-species susceptibility to prion infection (11, 27, 35).
Because nondenatured PrPSc molecules purified from prioninfected brains are highly aggregated and resistant to enzymatic deglycosylation, it is not possible to generate fully deglycosylated PrPSc molecules by directly treating samples of
infectious prions with glycosidases. Recently, Castilla et al.
showed that sPMCA could be used to propagate the characteristic phenotypic properties of several murine prion strains
faithfully, including their specific patterns of neuronal targeting (6). For the purposes of this study, we utilized sPMCA to
propagate two of these mouse-adapted prion strains with easily
distinguishable patterns of neuronal targeting, RML and 301C.
To prepare an appropriate sPMCA substrate, we used PNGase
F to deglycosylate native mouse PrPC under nondenaturing
conditions. Our previous studies showed that unglycosylated
PrPC prepared in this manner is a competent and, indeed,
necessary substrate for the in vitro propagation of mouse prions (26). Using this approach, we have been able to eliminate
PrP glycosylation without the need to mutate the PrP sequence, thereby avoiding a perturbation that could potentially
constrain the folding pathway of PrPSc molecules during prion
formation (25, 36).
Our neuropathological analysis revealed no observable differences between mice inoculated with glycosylated and mice
inoculated with unglycosylated PrPSc molecules. Two of the
most striking strain-dependent neuropathological differences
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FIG. 4. Regional neuropathology of mice infected with brain-derived and sPMCA-generated inocula. (A) PrP immunohistochemistry profiles
of animals inoculated with samples containing brain-derived 301C (f), UN-sPMCA(301C) (E), and Abl-sPMCA(301C) (Œ). (B) PrP immunohistochemistry profiles of animals inoculated with samples containing brain-derived RML (f), UN-sPMCA(RML) (E), and Abl-sPMCA(RML)
(Œ). (C) Vacuolation profile scores of animals inoculated with samples containing brain-derived 301C (f), UN-sPMCA(301C) (E), and AblsPMCA(301C) (Œ). (D) Vacuolation profile scores of animals inoculated with samples containing brain-derived RML (f), UN-sPMCA(RML)
(E), and Abl-sPMCA(RML) (Œ). Brain regions I and II, cerebral cortical layers 1 and 2; III and IV, cortical layers 3 and 4; V and VI; cortical
layers 5 and 6; H, hippocampus; C, cerebellum; BS, brain stem. The mean values (n ⫽ 4 to 9 animals/group) ⫾ standard errors of the means
are shown.

maintained by unglycosylated PrPSc molecules were (i) PrPSc
deposition in layers 3 and 4 of the cerebral cortex in 301Cinfected mice versus deposition throughout the entire thickness of the cortex in RML-infected mice and (ii) the appearance of punctate and larger PrPSc aggregates in the cerebellum
of 301C-infected mice versus a diffuse pattern of deposition in
RML-infected mice. Thus, our data indicate that the lack of
PrP glycosylation did not alter strain-specific neuronal targeting at either the cellular or regional level of the brain. Interestingly, another strain-dependent neuropathological feature
that was preserved when animals were inoculated with unglycosylated PrPSc molecules was the severity of vacuolation and
PrP deposition in specific brain regions. This phenomenon was
most noticeable in the cerebral cortex of RML-infected ani-

mals (Fig. 3; see Fig. S3 in the supplemental material). Further
work is required to understand why prion strains cause different rates of PrPSc deposition in specific brain regions.
As previously described by Tuzi et al., we observed that mice
inoculated with unglycosylated PrPSc molecules produced prions containing both glycosylated and unglycosylated PrP molecules (35). Furthermore, we found that the resulting PrPSc
molecules appeared to maintain strain-dependent patterns of
electrophoretic mobility following cleavage with proteinase K.
Since the precise location of proteinase K cleavage is most
likely determined by the core conformation of PrPSc, this observation suggests that PrPSc glycosylation is also unnecessary
for the maintenance of strain-specific differences in PrPSc conformations between RML and 301C during passage in animals.
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The cellular mechanism that underlies strain-dependent
prion neurotropism is currently unknown, but several possibilities exist. First, different neuronal subpopulations might possess different sets of recognition sites, which preferentially bind
to specific prion strains. Such putative recognition sites could
be PrPC molecules, and regional variation in PrPC glycosylation could provide a basis for differential strain susceptibility
(2, 32, 35). The structural differences between strains are quite
substantial, as judged by the strain-specific fluorescence pattern of luminescent polymers (31) or by Fourier transform
infrared spectroscopy (8), and may be sufficient in controlling
the strength of interactions with differentially expressed cellular ligands/receptors. Second, the efficiencies by which specific
neuronal subpopulations are able to propagate different prion
strains may vary, possibly because of regional variations in the
specificity or activity of chaperones or other putative cofactors.
Third, different prion strains could be cleared from different
parts of the brain with various efficiencies. Finally, different
prion strains may spread transsynaptically to specific regions of
the brain at different rates (1). More work is required to distinguish between these various possibilities. Recently, Mahal
et al. described an in vitro system that could potentially be
exploited to study the molecular basis by which cells preferentially propagate specific prion strains (23). Our current studies
show that PrPSc glycosylation does not play a role in that
process.
ACKNOWLEDGMENTS
We thank Nathan Deleault for helpful discussions and suggestions.
We thank Eve Kemble and Michael Miller for help in optimizing and
processing the histology slides. We thank David McGuire and Todd
Bissonnette for their expert veterinary services.
The National Institutes of Health provided financial support for this
study (2R01 NS046478, R01 NS055875, T32 AI007519, and R01
NS049173 to C.S.).
REFERENCES
1. Ayers, J. I., A. E. Kincaid, and J. C. Bartz. 2009. Prion strain targeting
independent of strain-specific neuronal tropism. J. Virol. 83:81–87.
2. Beringue, V., G. Mallinson, M. Kaisar, M. Tayebi, Z. Sattar, G. Jackson, D.
Anstee, J. Collinge, and S. Hawke. 2003. Regional heterogeneity of cellular
prion protein isoforms in the mouse brain. Brain 126:2065–2073.
3. Bruce, M. E. 1993. Scrapie strain variation and mutation. Br. Med. Bull.
49:822–838.
4. Carlson, G. A. 1996. Prion strains. Curr. Top. Microbiol. Immunol. 207:
35–47.
5. Carlson, G. A., D. T. Kingsbury, P. A. Goodman, S. Coleman, S. T. Marshall,
S. DeArmond, D. Westaway, and S. B. Prusiner. 1986. Linkage of prion
protein and scrapie incubation time genes. Cell 46:503–511.
6. Castilla, J., R. Morales, P. Saa, M. Barria, P. Gambetti, and C. Soto. 2008.
Cell-free propagation of prion strains. EMBO J. 27:2557–2566.
7. Castilla, J., P. Saa, C. Hetz, and C. Soto. 2005. In vitro generation of
infectious scrapie prions. Cell 121:195–206.
8. Caughey, B., G. J. Raymond, and R. A. Bessen. 1998. Strain-dependent
differences in beta-sheet conformations of abnormal prion protein. J. Biol.
Chem. 273:32230–32235.
9. Collinge, J., K. C. Sidle, J. Meads, J. Ironside, and A. F. Hill. 1996. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD.
Nature 383:685–690.
10. DeArmond, S. J., Y. Qiu, H. Sanchez, P. R. Spilman, A. Ninchak-Casey, D.
Alonso, and V. Daggett. 1999. PrPc glycoform heterogeneity as a function of
brain region: implications for selective targeting of neurons by prion strains.
J. Neuropathol. Exp. Neurol. 58:1000–1009.
11. DeArmond, S. J., H. Sanchez, F. Yehiely, Y. Qiu, A. Ninchak-Casey, V.
Daggett, A. P. Camerino, J. Cayetano, M. Rogers, D. Groth, M. Torchia, P.
Tremblay, M. R. Scott, F. E. Cohen, and S. B. Prusiner. 1997. Selective
neuronal targeting in prion disease. Neuron 19:1337–1348.
12. Deleault, N. R., J. C. Geoghegan, K. Nishina, R. Kascsak, R. A. Williamson,
and S. Supattapone. 2005. Protease-resistant prion protein amplification
reconstituted with partially purified substrates and synthetic polyanions.
J. Biol. Chem. 280:26873–26879.

5327

13. Deleault, N. R., B. T. Harris, J. R. Rees, and S. Supattapone. 2007. Formation of native prions from minimal components in vitro. Proc. Natl. Acad.
Sci. USA 104:9741–9746.
14. Endo, T., D. Groth, S. B. Prusiner, and A. Kobata. 1989. Diversity of oligosaccharide structures linked to asparagines of the scrapie prion protein.
Biochemistry 28:8380–8388.
15. Ermonval, M., D. Petit, A. Le Duc, O. Kellermann, and P. F. Gallet. 21
October 2008, posting date. Glycosylation-related genes are variably expressed depending on the differentiation state of a bioaminergic neuronal
cell line: implication for the cellular prion protein. Glycoconj. J. doi:10.1007/
s10719-008-9198-5
16. Fraser, H., and A. G. Dickinson. 1967. Distribution of experimentally induced scrapie lesions in the brain. Nature 216:1310–1311.
17. Geoghegan, J. C., P. A. Valdes, N. R. Orem, N. R. Deleault, R. A. Williamson,
B. T. Harris, and S. Supattapone. 2007. Selective incorporation of polyanionic molecules into hamster prions. J. Biol. Chem. 282:36341–36353.
18. Glatzel, M., K. Stoeck, H. Seeger, T. Luhrs, and A. Aguzzi. 2005. Human
prion diseases: molecular and clinical aspects. Arch. Neurol. 62:545–552.
19. Jones, E. M., and W. K. Surewicz. 2005. Fibril conformation as the basis of
species- and strain-dependent seeding specificity of mammalian prion amyloids. Cell 121:63–72.
20. King, C. Y., and R. Diaz-Avalos. 2004. Protein-only transmission of three
yeast prion strains. Nature 428:319–323.
21. Levavasseur, E., I. Laffont-Proust, E. Morain, B. A. Faucheux, N. Privat, K.
Peoc’h, V. Sazdovitch, J. P. Brandel, J. J. Hauw, and S. Haik. 2008. Regulating factors of PrP glycosylation in Creutzfeldt-Jakob disease—implications for the dissemination and the diagnosis of human prion strains. PLoS
ONE 3:e2786.
22. Locht, C., B. Chesebro, R. Race, and J. M. Keith. 1986. Molecular cloning
and complete sequence of prion protein cDNA from mouse brain infected
with the scrapie agent. Proc. Natl. Acad. Sci. USA 83:6372–6376.
23. Mahal, S. P., C. A. Baker, C. A. Demczyk, E. W. Smith, C. Julius, and C.
Weissmann. 2007. Prion strain discrimination in cell culture: the cell panel
assay. Proc. Natl. Acad. Sci. USA 104:20908–20913.
24. Makarava, N., and I. V. Baskakov. 2008. The same primary structure of the
prion protein yields two distinct self-propagating states. J. Biol. Chem. 283:
15988–15996.
25. Makarava, N., O. V. Bocharova, V. V. Salnikov, L. Breydo, M. Anderson, and
I. V. Baskakov. 2006. Dichotomous versus palm-type mechanisms of lateral
assembly of amyloid fibrils. Protein Sci. 15:1334–1341.
26. Nishina, K. A., N. R. Deleault, S. P. Mahal, I. Baskakov, T. Luhrs, R. Riek,
and S. Supattapone. 2006. The stoichiometry of host PrPC glycoforms modulates the efficiency of PrPSc formation in vitro. Biochemistry 45:14129–
14139.
27. Priola, S. A., and V. A. Lawson. 2001. Glycosylation influences cross-species
formation of protease-resistant prion protein. EMBO J. 20:6692–6699.
28. Prusiner, S. B. 1982. Novel proteinaceous infectious particles cause scrapie.
Science 216:136–144.
29. Prusiner, S. B., S. P. Cochran, D. F. Groth, D. E. Downey, K. A. Bowman,
and H. M. Martinez. 1982. Measurement of the scrapie agent using an
incubation time interval assay. Ann. Neurol. 11:353–358.
30. Rudd, P. M., M. R. Wormald, D. R. Wing, S. B. Prusiner, and R. A. Dwek.
2001. Prion glycoprotein: structure, dynamics, and roles for the sugars. Biochemistry 40:3759–3766.
31. Sigurdson, C. J., K. P. Nilsson, S. Hornemann, G. Manco, M. Polymenidou,
P. Schwarz, M. Leclerc, P. Hammarstrom, K. Wuthrich, and A. Aguzzi. 2007.
Prion strain discrimination using luminescent conjugated polymers. Nat.
Methods 4:1023–1030.
32. Somerville, R. A., S. Hamilton, and K. Fernie. 2005. Transmissible spongiform encephalopathy strain, PrP genotype and brain region all affect the
degree of glycosylation of PrPSc. J. Gen. Virol. 86:241–246.
33. Tanaka, M., P. Chien, N. Naber, R. Cooke, and J. S. Weissman. 2004.
Conformational variations in an infectious protein determine prion strain
differences. Nature 428:323–328.
34. Tanaka, M., P. Chien, K. Yonekura, and J. S. Weissman. 2005. Mechanism
of cross-species prion transmission: an infectious conformation compatible
with two highly divergent yeast prion proteins. Cell 121:49–62.
35. Tuzi, N. L., E. Cancellotti, H. Baybutt, L. Blackford, B. Bradford, C. Plinston, A. Coghill, P. Hart, P. Piccardo, R. M. Barron, and J. C. Manson. 2008.
Host PrP glycosylation: a major factor determining the outcome of prion
infection. PLoS Biol. 6:e100.
36. Vanik, D. L., K. A. Surewicz, and W. K. Surewicz. 2004. Molecular basis of
barriers for interspecies transmissibility of mammalian prions. Mol. Cell
14:139–145.
37. Vincent, B., E. Paitel, P. Saftig, Y. Frobert, D. Hartmann, B. De Strooper,
J. Grassi, E. Lopez-Perez, and F. Checler. 2001. The disintegrins
ADAM10 and TACE contribute to the constitutive and phorbol esterregulated normal cleavage of the cellular prion protein. J. Biol. Chem.
276:37743–37746.
38. Wang, F., F. Yang, Y. Hu, X. Wang, X. Wang, C. Jin, and J. Ma. 2007.

5328

PIRO ET AL.

Lipid interaction converts prion protein to a PrP(Sc)-like proteinase
K-resistant conformation under physiological conditions. Biochemistry
46:7045–7053.
39. Wong, C., L. W. Xiong, M. Horiuchi, L. Raymond, K. Wehrly, B. Chesebro,
and B. Caughey. 2001. Sulfated glycans and elevated temperature stimulate
PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.
EMBO J. 20:377–386.

J. VIROL.
40. Yadavalli, R., R. P. Guttmann, T. Seward, A. P. Centers, R. A. Williamson,
and G. C. Telling. 2004. Calpain-dependent endoproteolytic cleavage of
PrPSc modulates scrapie prion propagation. J. Biol. Chem. 279:21948–
21956.
41. Zuegg, J., and J. E. Gready. 2000. Molecular dynamics simulation of human
prion protein including both N-linked oligosaccharides and the GPI anchor.
Glycobiology 10:959–974.

